Sleuthing the Source of Regeneration by MSCs  by Pittenger, Mark
new hair shaft becomes prominently gray.
Consistent with an effect of genotoxic
stress on the MSCs, mice with a mutation
in the DNA damage checkpoint kinase
ATM (mutated in ataxia-telangiectasia)
showed graying at a lower dose of ionizing
radiation and a significant increase in the
appearance of EPMs within the niche.
A particularly striking finding in the
study is that, despite these profound
effects of DNA damage on MSCs, the
authors find no evidence of apoptosis or
senescence in these failing stem cells.
To address this question further, they irra-
diated mice deficient in p53 or deficient in
the INK4A/ARF locus encoding both the
CDK inhibitor p16 and the p53 regulator
p19ARF. Both p53 and INK4A/ARF
have been clearly linked to the cellular
response to DNA damage, to organismal
aging, and to stem cell aging (Sharpless
andDePinho, 2007). The INK4A/ARF locus
is one of the critical targets of the poly-
combproteinbmi-1,which inhibitsexpres-
sion of INK4A/ARF. Loss of bmi-1 dramat-
ically impairs stem cell self-renewal in part
through the derepression of p16 and
p19ARF. Surprisingly, deletion of p53 or
INK4A/ARF had no effect on hair graying
induced by ionization radiation. Similarly,
depletion of MSCs and the appearance
of EPMs within the niche were not depen-
dent on p53 or INK4A/ARF. Instead, geno-
toxic stress triggers rapid differentiation of
quiescent MSCs through a process that
does not require these common check-
points.
These findings in MSCs are perhaps
related, in part, to those in aging HSCs
and in muscle stem cells (Figure 1). The
altered cell fate of aging HSCs toward
the myeloid lineage (Rossi et al., 2005)
and the aberrant differentiation of muscle
stem cells toward fibrogenic fates (Brack
et al., 2007) may also reflect a subtler
process by which aging or genotoxic
stress influences cell fate in many tissue
stem cell populations. In the case of irradi-
ated MSCs, DNA damage triggers a rapid
and complete loss of self-renewal, result-
ing in local differentiation within the niche.
In other stem cell populations, these alter-
ations in self-renewal or differentiation
with aging may be caused by accumu-
lated DNA damage, altered signaling,
epigenetic changes, or other stimuli. It
will be important to determine whether
this type of differentiation within the niche
seen in MSCs is also a feature of other
stem cells in settings of advancing age
or in response to genotoxic stress. The
findings of Inomata and colleagues su-
ggest that strategies that interfere with
this loss of self-renewal may delay stem
cell aging and help to preserve tissue
function in the face of genotoxic stress
encountered by stem cells.
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Mesenchymal stem cells (MSCs) can differentiate into useful cell types and also have the ability to modulate
inflammation. In this issue of Cell Stem Cell, Lee et al. (2009) investigate the production of the soluble inflam-
mation inhibitor TSG-6 by MSCs.Cellular therapy is a promising field, but
cells tend to be more complicated than
single therapeutic molecules, considering
their source of isolation, ex vivo expan-
sion, their proper handling and delivery,
the potential clinical outcome(s), and their
subsequent evaluation. In this regard,
some have suggested that cells are not8 Cell Stem Cell 5, July 2, 2009 ª2009 Elsevamenable to development as therapeu-
tics, but rather, they will help us to identify
factors to pursue as drugs. Another view
is that cells hold great promise as thera-
peutic agents, as a source for identifying
‘‘druggable’’ factors, and as a manipulat-
able platform for understanding biologics
and medicine. Therefore, continuing toier Inc.evaluate cells for therapeutic potential is
essential. MSCs (mesenchymal stem
cells/multipotent stromal cells) are one
of the current cell types being studied in
many labs as a therapeutic, as a source
of factors to improve tissue repair, and
as a paradigm for many aspects of cell-
cell interaction during tissue repair. One
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about MSC cellular therapy
relates to the fact that positive
results are obtained even where
few input cells can be identified.
In this issue, Prockop and col-
leagues sought to identify repar-
ative soluble factors that may be
produced by MSCs that become
trapped in the lungs of i.v. infused
animalsand thatmayenhance the
tissue regeneration process (Lee
et al., 2009). This work identifies
the production of TSG-6, also
known as TNAIP-6 or TNFa-
induced protein 6 and a regulator
of inflammation, as a soluble
circulating factor that improves
cardiac remodeling following in-
farction.
Lee et al. examined the fate
of human MSCs delivered i.v. to
mice with a permanent LAD liga-
tion as an experimental infarct
and noted the inherent improve-
ment in cardiac physiology
despite the apparent lack of
long-termMSC engraftment. The
authors examined mRNA pro-
duced shortly after the transplantation of
hMSCs into mice and sought the microar-
ray identification of factors, both mouse
and human, that result from trapping and
residence (embolization) of hMSCs in the
lungs. Several human mRNAs of interest
were identified and further evaluated
by RT-PCR, but their efforts focused on
TSG-6 as a known anti-inflammatory
molecule. Experimentally, intravenously
delivered hMSCs were found to decrease
plasmin levels in infracted animals, but
not if the cells were transduced with
a siRNA for TSG-6. The authors noted
a decrease in matrix metaloproteinase
activityanddecreased infiltrationofmono-
cytes and granulocytes in the infracted
hearts of animals receiving hMSCs, which
was not as pronounced when the hMSCs
harbored the TSG-6 siRNA. These bio-
chemical and histological results were
accompanied by the noted improvement
in heart remodeling and functional mea-
surements of infracted animals treated
with hMSCs. The hearts of animals re-
ceiving the hMSCs with a scrambled
siRNA also fared better than those treated
with the hMSCs with TSG-6 siRNA. Thus,
TSG-6 joins the ranks of soluble factors
produced by hMSCs that modulate
inflammation/granulation in damaged
tissue.
The MSCs, as produced in culture in
most labs, have an average diameter of
20–25 mM and therefore do not travel
far in the vasculature before becoming
stationary. That said, MSCs are deform-
able and do traverse capillaries and also
can extravasate to the immediate tissues
(Toma et al., 2009). Numerous studies
have shown that MSCs migrate to and
accumulate at the sites of tissue damage
and inflammation, but this subset always
appears to be a small fraction of the deliv-
ered cells. Studies have shown that only
a small portion of injected MSCs (1%–
2%) are present after 1 week and may
decline further. It is important to note
that, although MSCs propagate readily in
culture, there is little evidence for their
in vivo proliferation, at least in part due
to theMSC trait of being highly contact in-
hibited.
In multiple studies, intravenous infusion
of hMSCs has been found to improve
cardiac function following infarction, prob-
ably by limiting inflammatory responses in
the short term and improving cardiac
remodeling in the long term. Clinical
trials are underway with hMSCs but are
not likely to decipher the mecha-
nisms responsible for improve-
ment. In preclinical animal
studies, infused MSCs have
been found in the infracted heart
tissue of recipient animals but
in fewer numbers than might be
expected to produce such rela-
tively dramatic and long-lasting
changes (evaluated over 3–6
months). Therefore, attention has
turned to the early events ofMSC
delivery, when more cells are
clearly present and when inflam-
mation is most pronounced.
Studies to evaluate the interac-
tion of MSCs with cells of the
immune system, both in the allo-
geneic context and the autolo-
gous setting, have shown that
MSCs can reduce inflammatory
responses. With the addition of
TSG-6, at least 11 factors now
havebeen identified asproduced
by MSCs that reduce immune
cell inflammation, including
TGFb, HGF, PGE-2, IL-6, IL-10,
IL-1Rag, iNOS, IDO, Gal-1, and
HLA-G (Figure 1; Di Nicola et al.,
2002; Aggarwal and Pittenger, 2005; Na-
sef et al., 2007; Sato et al., 2007; Ortiz
et al., 2007; Kadri et al., 2005; Amado
et al., 2006). These proteins are all soluble
factors, but one can imagine that a few
MSCs at the site of tissue damage can
produce enough of these agents to alter
the course of the local inflammatory
response.
There is continued high interest in
cellular therapy for the heart because of
the inherent lack of regeneration in the
adult. Whereas blood cells turn over every
120 days and even the skeleton is
completely renewed in 6 years, a recent
study based on C14 dating calculates
that the heart of a 50-year-old person
still retains 55% of the cardiomyocytes
present at birth (Bergmann et al., 2009).
In the case of hearts damaged by experi-
mental vascular occlusion, local injection
or i.v. infusion of MSCs have been found
to improve perfusion and heart function
with MSCs retained in the damaged heart
tissue (see Amado et al., 2006 and refer-
ences therein). In the current work by Lee
et al. (2009), only perhaps 1500 of the
2 3 106 delivered hMSCs could be de-
tected in the infracted mouse hearts by
a sensitive PCR method, but it would be
Figure 1. MSC Interaction with Immune Cells during
Inflammation Results in the Production of Many Factors that
Modify Immune Cell Activities and Moderate the
Inflammatory Environment
MSCs produce a number of cytokines constitutively, but the inflamma-
tory environment of damaged tissue results in complex interaction with
responding immune cells. Whether it is the epithelial damage caused
by GvHD, a recent cardiac infarct, or other damage, MSCs have
been reported to improve the outcome in various animal models and
in clinical trials. In the inflammatory environment, MSC interactions
with T cells, macrophages, dendritic cells, etc. usually result in inhibi-
tion of inflammation. Many factors have been identified as contributing
to this response, and in this issue of Cell Stem Cell, Prockop and
colleagues present evidence for TSG-6 as another important factor.Cell Stem Cell 5, July 2, 2009 ª2009 Elsevier Inc. 9
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were located in thesitesof infarct damage.
A discussion of the evidence for endoge-
nous cells as a source of regenerative
cells for the heart will have to wait for
another day.
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